Mayo Clinic-ko ikertzaileekin lankidetzan egindako argitalpenak (5)

2024

  1. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

    Blood Advances

2020

  1. Correction to: A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity (Acta Neuropathologica, (2019), 138, 2, (237-250), 10.1007/s00401-019-02026-8)

    Acta Neuropathologica

2018

  1. A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers

    Brain, Vol. 141, Núm. 10, pp. 2895-2907

2012

  1. Cardiovascular risk factors, cortisol, and amyloid-β deposition in Alzheimer's Disease Neuroimaging Initiative

    Alzheimer's and Dementia, Vol. 8, Núm. 6, pp. 483-489

2011

  1. Factors affecting Aβ plasma levels and their utility as biomarkers in ADNI

    Acta Neuropathologica, Vol. 122, Núm. 4, pp. 401-413